China Oncology ›› 2022, Vol. 32 ›› Issue (3): 243-250.doi: 10.19401/j.cnki.1007-3639.2022.03.007
• Article • Previous Articles Next Articles
CHEN Xi1, ZENG Xiaoying2, CHEN Jiayan1, LIU Fei1, TANG Xi1()
Received:
2022-01-03
Revised:
2022-02-08
Online:
2022-03-30
Published:
2022-04-02
Contact:
TANG Xi
E-mail:olivia9tang@126.com
CLC Number:
CHEN Xi, ZENG Xiaoying, CHEN Jiayan, LIU Fei, TANG Xi. The clinical value of mismatch repair protein combined with serum tumor markers and Ki-67 proliferation index in the prognostic evaluation of colorectal cancer[J]. China Oncology, 2022, 32(3): 243-250.
Tab. 1
Relationship between mismatched repair protein expression and basic pathological parameters and observed indicators of patients"
Subgroup | dMMR | pMMR | χ2 value | P value | Subgroup | dMMR | pMMR | χ2 value | P value | |
---|---|---|---|---|---|---|---|---|---|---|
Gender | 0.205 | 0.651 | Positive | 8 | 104 | |||||
Male | 17 | 111 | Negative | 21 | 101 | |||||
Female | 12 | 94 | Vascular invasion | 0.733 | 0.392 | |||||
Age/year | 0.098 | 0.755 | Positive | 7 | 36 | |||||
≤65 | 11 | 84 | Negative | 22 | 169 | |||||
>65 | 18 | 121 | Nerve invasion | 0.597 | 0.440 | |||||
Tumor primary site | 18.346 | <0.001 | Positive | 1 | 15 | |||||
Right side | 20 | 59 | Negative | 28 | 190 | |||||
Left side | 9 | 146 | Ki-67 | 10.818 | 0.001 | |||||
Differentiation type | 38.050 | <0.001 | Low positive rate | 15 | 47 | |||||
High and middle adenocarcinoma | 9 | 170 | High positive rate | 14 | 158 | |||||
Poorly, mucinous adenocarcinoma | 20 | 35 | Preoperative CEA | 5.309 | 0.021 | |||||
Stage | 14.656 | 0.002 | Normal | 22 | 109 | |||||
Ⅰ | 1 | 32 | High | 7 | 96 | |||||
Ⅱ | 20 | 68 | Preoperative C19-9 | 2.646 | 0.104 | |||||
Ⅲ | 8 | 97 | Normal | 19 | 162 | |||||
Ⅳ | 0 | 8 | High | 10 | 43 | |||||
T stage | 9.414 | 0.024 | Preoperative CA72-4 | 12.340 | <0.001 | |||||
T1 | 1 | 13 | Normal | 17 | 175 | |||||
T2 | 0 | 28 | High | 12 | 30 | |||||
T3 | 22 | 149 | Preoperative CA12-5 | 0.083 | 0.774 | |||||
T4 | 6 | 15 | Normal | 26 | 180 | |||||
Lymph node metastasis | 5.454 | 0.020 | High | 3 | 25 |
Tab. 2
Univariate prognostic analysis"
Prognostic factor | Total | Deaths | Survival n(%) | χ2 value | P value |
---|---|---|---|---|---|
Gender | 0.471 | 0.492 | |||
Male | 127 | 17 | 110 (86.6) | ||
Female | 102 | 17 | 85 (83.3) | ||
Age/year | 3.523 | 0.061 | |||
≤65 | 92 | 9 | 83 (90.2) | ||
>65 | 137 | 25 | 112 (81.8) | ||
Tumor primary site | 2.127 | 0.145 | |||
Right side | 78 | 8 | 70 (89.7) | ||
Left side | 151 | 26 | 125 (82.8) | ||
Differentiation type | 1.474 | 0.225 | |||
High and middle adenocarcinoma | 174 | 23 | 151 (86.8) | ||
Poorly, mucinous adenocarcinoma | 55 | 11 | 44 (80.0) | ||
Stage | 286.080 | <0.001 | |||
Ⅰ | 33 | 0 | 33 (100.0) | ||
Ⅱ | 88 | 1 | 87 (98.9) | ||
Ⅲ | 100 | 25 | 75 (75.0) | ||
Ⅳ | 8 | 8 | 0 (0.0) | ||
T stage | 6.481 | 0.090 | |||
T1 | 14 | 0 | 14 (100.0) | ||
T2 | 28 | 1 | 27 (96.4) | ||
T3 | 167 | 29 | 138 (82.6) | ||
T4 | 20 | 4 | 16 (80.0) | ||
Lymph node metastasis | 37.510 | <0.001 | |||
Positive | 122 | 2 | 120 (98.4) | ||
Negative | 107 | 32 | 75 (70.1) | ||
Vascular invasion | 0.716 | 0.398 | |||
Positive | 43 | 8 | 35 (81.4) | ||
Negative | 186 | 26 | 160 (86.0) | ||
Nerve invasion | 2.606 | 0.106 | |||
Positive | 16 | 0 | 16 (100.0) | ||
Negative | 213 | 34 | 179 (84.0) | ||
MMR | 6.063 | 0.014 | |||
dMMR | 29 | 0 | 29 (100.0) | ||
pMMR | 200 | 34 | 166 (83.0) | ||
Ki-67 | 2.598 | 0.107 | |||
Low positive rate | 59 | 5 | 54 (91.5) | ||
High positive rate | 170 | 29 | 141 (82.9) | ||
Preoperative CEA | 10.320 | 0.001 | |||
Normal | 130 | 11 | 119 (91.5) | ||
High | 99 | 23 | 76 (76.8) | ||
Preoperative C19-9 | 2.731 | 0.098 | |||
Normal | 179 | 23 | 156 (87.2) | ||
High | 50 | 11 | 39 (78.0) | ||
Preoperative CA72-4 | 9.804 | 0.002 | |||
Normal | 190 | 22 | 168 (88.4) | ||
High | 39 | 12 | 27 (69.2) | ||
Preoperative CA12-5 | 2.103 | 0.147 | |||
Normal | 204 | 28 | 176 (86.3) | ||
High | 25 | 6 | 19 (76.0) |
Tab. 3
Multivariate COX regression analysis of prognostic factors"
Variable | survival time | |||||
---|---|---|---|---|---|---|
B | SE | Wald χ2 | P value | Exp (B) | HR (95.0% CI) | |
Preoperative CA72-4 | 0.850 | 0.407 | 4.374 | 0.036 | 2.341 | 1.055-5.193 |
Preoperative CEA | 0.047 | 0.416 | 0.013 | 0.910 | 1.048 | 0.464-2.369 |
Stage | 3.556 | 0.487 | 53.314 | 0.000 | 35.036 | 13.487-91.014 |
Lymph node metastasis | -0.785 | 0.828 | 0.898 | 0.343 | 0.456 | 0.090-2.312 |
MMR | 13.344 | 358.219 | 0.001 | 0.970 | 623 983.018 | 0.000 |
[1] |
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
doi: 10.3322/caac.v71.1 |
[2] | 吴春晓, 顾凯, 龚杨明, 等. 2015年中国结直肠癌发病和死亡情况分析[J]. 中国癌症杂志, 2020, 30(4): 241-245. |
WU C X, GU K, GONG Y M, et al. Analysis of incidence and mortality of colorectal cancer in China, 2015[J]. China Oncol, 2020, 30(4): 241-245. | |
[3] | 姚宏伟, 吴鸿伟, 刘荫华. 美国癌症联合委员会第8版结直肠癌分期更新及其“预后和预测”评价体系[J]. 中华胃肠外科杂志, 2017, 20(1): 24-27. |
YAO H W, WU H W, LIU Y H. Improvement of prognostic and predictive network of colorectal cancer based upon the 8th edition of AJCC colorectal cancer staging system[J]. Chin J Gastrointest Surg, 2017, 20(1): 24-27. | |
[4] | 吴敏, 龙静, 杨瑶. 血清肿瘤标志物联合检验应用于结直肠癌临床诊断的价值分析[J]. 国际检验医学杂志, 2017, 38(17): 2484-2486. |
WU M, LONG J, YANG Y. Value of combined test of serum tumor markers in clinical diagnosis of colorectal cancer[J]. Int J Lab Med, 2017, 38(17): 2484-2486. | |
[5] | 李勇, 姜世平, 高霞. Ki-67和CK20及CEA的表达与结直肠癌临床病理特征的关系及意义[J]. 中国现代普通外科进展, 2017, 20(5): 394-396. |
LI Y, JIANG S P, GAO X. Relationship and significance between the expression of Ki-67, CK20 and CEA and clinicopathological features of colorectal cancer[J]. Chin J Curr Adv Gen Surg, 2017, 20(5): 394-396. | |
[6] | RUBENSTEIN J H, ENNS R, HEIDELBAUGH J, et al. American gastroenterological association institute guideline on the diagnosis and management of lynch syndrome[J]. Gastroenterology, 2015, 149(3): 777-782; quize16-7. |
[7] |
BENSON A B, VENOOK A P, AL-HAWARY M M, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021. 19(3): 329-359.
doi: 10.6004/jnccn.2021.0012 |
[8] | 中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J]. 中华外科杂志, 2020, 58(8): 561-585. |
National Health Commission of the People's Republic of China. Chinese protocol of diagnosis and treatment of colorectal cancer (2020 edition)[J]. Chin J Surg, 2020, 58(8): 561-585. | |
[9] | 韩安家, 黄艳, 来茂德. 肿瘤病理诊断规范(结直肠癌)[J]. 中华病理学杂志, 2016, 45(12): 822-824. |
HAN A J, HUANG Y, LAI M D. Diagnostic criteria of tumor pathology (colorectal cancer)[J]. Chin J Pathol, 2016, 45(12): 822-824. | |
[10] | 于显博, 王海江, 孙振强, 等. 散发性结直肠癌患者错配修复基因蛋白表达水平及其临床意义[J]. 中国全科医学, 2014, 17(8): 883-887. |
YU X B, WANG H J, SUN Z Q, et al. Mismatch repair gene protein expression and clinical significance in patients with sporadic colorectal carcinoma[J]. Chin Gen Pract, 2014, 17(8): 883-887. | |
[11] |
JUNG S B, LEE H I, OH H K, et al. Clinico-pathologic parameters for prediction of microsatellite instability in colorectal cancer[J]. Cancer Res Treat, 2012, 44(3): 179-186.
doi: 10.4143/crt.2012.44.3.179 |
[12] |
KIM C G, AHN J B, JUNG M, et al. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers[J]. Br J Cancer, 2016, 115(1): 25-33.
doi: 10.1038/bjc.2016.161 |
[13] |
NICOLINI A, FERRARI P, DUFFY M J, et al. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival[J]. Arch Surg, 2010, 145(12): 1177-1183.
doi: 10.1001/archsurg.2010.251 |
[14] | 陈舒颖, 邱芳华, 李秋明, 等. 血清DCD、CA199、CA724和CEA联合检测对大肠癌的诊断价值[J]. 实用医学杂志, 2017, 33(15): 2482-2485. |
CHEN S Y, QIU F H, LI Q M, et al. Value of combined detection of serum DCD, CA199, CA724, and CEA in diagnosis of colorectal cancer[J]. J Pract Med, 2017, 33(15): 2482-2485. | |
[15] | 陈蕾, 姜北海, 邸佳柏, 等. 术前检测癌胚抗原和糖链抗原199对结直肠癌Ⅱ~Ⅲ期患者预后的判断价值[J]. 中华胃肠外科杂志, 2015(9): 914-919. |
JIANG B H, DI J B, ZHANG C H, et al. Predictive value of preoperative detection of CEA and CA199 for prognosis in patients with stage Ⅱ-Ⅲ colorectal cancer[J]. Chin J Gastrointest Surg, 2015(9): 914-919. | |
[16] | 邹超世, 林英, 刘康海, 等. 多种肿瘤标志物联合检测诊断结直肠癌的临床价值及预后监测研究[J]. 国际检验医学杂志, 2018, 39(23): 2960-2963. |
ZOU C S, LIN Y, LIU K H, et al. Clinical value and prognostic monitoring of combined detection of multiple tumor markers in the diagnosis of colorectal cancer[J]. Int J Lab Med, 2018, 39(23): 2960-2963. | |
[17] |
KOGANEMARU S, INOSHITA N, MIURA Y, et al. Prognostic value of programmed death-ligand 1 expression in patients with stage Ⅲ colorectal cancer[J]. Cancer Sci, 2017, 108(5): 853-858.
doi: 10.1111/cas.13229 |
[18] | 傅桂霞. Array-ELISA检测6项肿瘤标志物诊断结直肠癌的临床价值分析[J]. 川北医学院学报, 2017, 32(5): 781-784. |
FU G X. Clinical value of Array-ELISA in detecting six tumor markers in diagnosis of colorectal cancer[J]. J North Sichuan Med Coll, 2017, 32(5): 781-784. | |
[19] | 史汉蒙, 司君利, 崔伟丽, 等. 肿瘤相关巨噬细胞计数、基质金属蛋白酶-2及Ki-67的表达与结直肠癌预后的关系[J]. 中华消化杂志, 2015(6): 405-407. |
SHI H M, SI J L, CUI W L, et al. Relationship between tumor associated macrophage count, matrix metalloproteinase-2 and Ki-67 expression and prognosis of colorectal cancer[J]. Chin J Dig, 2015(6): 405-407. | |
[20] |
MELLING N, KOWITZ C M, SIMON R, et al. High Ki-67 expression is an independent good prognostic marker in colorectal cancer[J]. J Clin Pathol, 2016, 69(3): 209-214.
doi: 10.1136/jclinpath-2015-202985 |
[1] | GAO Heli, XU Jin, YU Xianjun. Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021 [J]. China Oncology, 2022, 32(9): 772-778. |
[2] | ZHANG Rihong, GUO Yu, LIANG Yun, CHEN Luohai, CHEN Jie, WANG Wei. Prognostic significance of adjuvant chemotherapy in patients with gastric neuroendocrine carcinoma [J]. China Oncology, 2022, 32(9): 807-817. |
[3] | CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong. Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer [J]. China Oncology, 2022, 32(7): 588-595. |
[4] | QIAN Yao, LIU Feng. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer [J]. China Oncology, 2022, 32(7): 643-649. |
[5] | LIU Yanquan, HU Xiaomei, YIN Yue, LIN Lin, SHEN Jianzhen, CHEN Yuting, TANG Huanwen. A retrospective study and clinical analysis of post-transplant lymphoproliferative disorder [J]. China Oncology, 2022, 32(7): 650-656. |
[6] | QU Yiping, HOU Peng. Genetic characteristics and prognosis of metastatic thyroid cancer in children [J]. China Oncology, 2022, 32(5): 373-379. |
[7] | MA Guang, OU Xiaomin, HU Chaosu, SONG Shaoli, YANG Zhongyi. Value of pretreatment 18F-FLT PET/CT and 18F-FDG PET/CT uptake heterogeneity for early prediction of treatment outcome in locally advanced nasopharyngeal carcinoma [J]. China Oncology, 2022, 32(4): 309-315. |
[8] | YANG Yilan, ZHAO Xu, CHEN Xingxing, WANG Xuanyi, JIN Kairui, ZHANG Zhen, SHAO Zhimin, GUO Xiaomao, YU Xiaoli. A single-center prognotic analysis of breast ductal carcinoma in situ [J]. China Oncology, 2022, 32(3): 228-233. |
[9] | WANG Zimao, CAO Yuan, WANG Qiying. Construction and validation of the survival prediction model for patients with cutaneous spindle cell melanoma [J]. China Oncology, 2022, 32(3): 234-242. |
[10] | HOU Qinghua, ZHONG Yanfeng, LIU Linzhuang, WU Liusheng, LIU Jixian. Expression, prognostic value of CBX3 in lung adenocarcinoma and its effect on biological behavior of cancer cells [J]. China Oncology, 2022, 32(2): 152-160. |
[11] | JIA Zhenzhen, HE Shuang, LI Yangyang, WEN Feifei, XU Xiaoyang, GUO Ningjie, WU Shuhua. Correlations between expressions of DPD, LC3 and P62 in colorectal cancer and their clinical significance [J]. China Oncology, 2022, 32(1): 24-33. |
[12] | MA Yifei , LIANG Xinjun , WEI Shaozhong . Prognostic value of inflammatory and immune markers in resectable colorectal cancer [J]. China Oncology, 2021, 31(9): 845-851. |
[13] | LEI Yajie , GAO Yi , WANG Zhijie , CHENG Xi , YANG Yufei , ZHOU Hongyu , CHEN Lihua , CHEN Yixin , LI Haoran , LI Ziting , WU Xiaohua . Potential role of lymphadenectomy in patients with ovarian cancer (ⅠC-ⅡA): a retrospective trial [J]. China Oncology, 2021, 31(8): 740-745. |
[14] | ZHU Yihui, LI Ting, HU Xichun. Clinical research progress and prospect of trastuzumab deruxtecan [J]. China Oncology, 2021, 31(8): 754-761. |
[15] | ZHANG Yingqiang , LIN Yansong . Application and research progress of 90 Y microspheres internal radiation therapy in colorectal cancer with liver metastasis [J]. China Oncology, 2021, 31(8): 762-768. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd